The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma
Abstract
Purpose: Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNα2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics. Patients and Methods: Forty-three patients with HCC (34), and fibrolamellar HCC (FLHCC; nine) were treated with continuous intravenous (IV) FU (200 mg/m 2/d × 21 every 28 days) and subcutaneous (SC) rIFNα2b (4 million U/m 2) three times weekly. Survival was determined in all 43 patients, and response could be assessed in 28 HCC and 8 FLHCC patients. Results: The median ages of the patients were 63.5 and 19 years among HCC and FLHCC patients, respectively. Liver cirrhosis was present among 71% of HCC patients but among none of the FLHCC patients. Nine of 36 (25%; four of 28 [14%] HCC patients; five of eight [62.5%] FLHCC patients) patients in which a response could be assessed had a complete response (CR; one patient with FLHCC and no patients with HCC) or partial response (PR; eight patients [four HCC and four FLHCC patients]). Four HCC patients underwent resection, and two had a histologic CR; one HCC patient with a PR underwent orthotopic liver transplantation. One FLHCC patient also underwent resection without clear margins. Overall median survival was 19.5 months (95% confidence interval [CI], 11.2 to 27.8 months); median survival was 15.5 months (95% CI, 8.5 to 22.5 months) among HCC patients, and that of FLHCC patients was 23.1 months (95% CI, 10.3 to 35.9 months). Overall grade 3 or 4 toxicity included stomatitis (32.6%), fatigue (4.7%), and hematologic toxicity (9.3%). Conclusion: Continuous IV FU and thrice-weekly SC rIFNα2b are an effective treatment, especially for FLHCC, and may have a neoadjuvant role in this disease. This regimen has activity in HCC and can be tolerated even by cirrhotic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Hassan, M. M., Hwang, L.-Y., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002) · Hepatology · doi:10.1053/jhep.2002.36780 · Cited by 762
Self-citation
Cited by
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J.-F. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 372
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Metadata
- Authors
- Patt, Y. Z., Hassan, M. M., Lozano, R. D., Brown, T. D., Vauthey, J. N., Curley, S. A., & Ellis, L. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-02-01
- Volume
- 21
- Issue
- 3
- Pages
- 421-427
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2050565603
- Cited by
- 200
- References
- 2
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.